StreetInsider.com News Articles

Form 8-K Kyverna Therapeutics, For: Jul 08

Thu, 09 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260709/26749553.html

Form 8-K Kyverna Therapeutics, For: Jul 08

Thu, 09 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260709/26749553.html

Kyverna Therapeutics names Ritesh Srivastava as chief legal officer

Mon, 22 Jun 2026 08:02:08 -0400

Kyverna Therapeutics (Nasdaq: KYTX) appointed Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026, according to a company statement.

Srivastava joins from BPGbio, where he served as General Counsel. Before that, he was Global Compliance Officer at Spectrum Pharmaceuticals, advising the board on corporate governance, risk management, and public company disclosure matters. He also previously served as Director of Compliance and Investigations at Avanir Pharmaceuticals.

Earlier in his career, Srivastava was a federal prosecutor with the U.S. Department of Justice, where he led investigations into healthcare fraud and anti-kickback cases. He also practiced as a litigator at Cooley LLP

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Mon, 22 Jun 2026 08:00:00 -0400

EMERYVILLE, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026. Mr. Srivastava brings extensive experience spanning legal, corporate strategy, compliance, and risk management, which will further support Kyverna as it advances miv-cel (mivocabtagene autoleucel, KYV-101) towards a potential first approval in stiff person syndrome and transitions to a commercial-stage organization.

“Ritesh is a key addition to Kyverna as we prepare for commercialization and

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Mon, 22 Jun 2026 08:00:00 -0400

“Ritesh is a key addition to Kyverna as we prepare for commercialization and

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Mon, 22 Jun 2026 08:00:00 -0400

“Ritesh is a key addition to Kyverna as we prepare for commercialization and

Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition

Mon, 22 Jun 2026 08:00:00 -0400

“Ritesh is a key addition to Kyverna as we prepare for commercialization and

H.C. Wainwright Reiterates Buy Rating on Kyverna Therapeutics Inc (KYTX)

Thu, 04 Jun 2026 06:41:37 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $25.00 price target on Kyverna Therapeutics Inc (NASDAQ: KYTX).

The analyst commented: "Kyverna’s updated Phase 1 COMPARE data at EULAR look meaningfully positive for miv-cel’s broader autoimmune activity: all six ACPA-positive, treatment-refractory RA patients had reduced disease activity after one infusion, 66.6% achieved ACR70 by Week 36, disease-associated autoantibodies declined for up to 52 weeks, B cells repopulated with a naïve/transitional phenotype, and there were no high-grade CRS or ICANS events. It is important to consider that these were difficult-to-treat patients who had failed a median of 6.5 prior biologic

Kyverna presents updated data on miv-cel for rheumatoid arthritis

Wed, 03 Jun 2026 08:03:57 -0400

Kyverna Therapeutics Inc. (NASDAQ: KYTX) presented updated data from its Phase 1 trial of miv-cel in patients with treatment-refractory rheumatoid arthritis at the European Alliance of Associations for Rheumatology Congress in London.

The COMPARE trial enrolled six patients with anti-citrullinated protein antibody-positive rheumatoid arthritis who had failed a median of 6.5 prior biologic treatments. Patients received a single infusion of miv-cel CAR T cells following lymphodepletion, with follow-up ranging up to 52 weeks.

According to the company, 66.6% of patients met the American College of Rheumatology improvement criteria response by Week 36. The treatment resulted in depletion of CD19+ B cells and

Kyverna presents updated data on miv-cel for rheumatoid arthritis

Wed, 03 Jun 2026 08:03:57 -0400

According to the company, 66.6% of patients met the American College of Rheumatology improvement criteria response by Week 36. The treatment resulted in depletion of CD19+ B cells and

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Wed, 03 Jun 2026 08:00:00 -0400

Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36

Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset

Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date¹

Data reinforce miv-cel’s differentiated clinical profile and opportunity to change the treatment paradigm across a variety of autoimmune diseases

EMERYVILLE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Wed, 03 Jun 2026 08:00:00 -0400

Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36

Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset

Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date¹

Data reinforce miv-cel’s differentiated clinical profile and opportunity to change the treatment paradigm across a variety of autoimmune diseases

EMERYVILLE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Wed, 03 Jun 2026 08:00:00 -0400

Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36

Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset

Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date¹

Data reinforce miv-cel’s differentiated clinical profile and opportunity to change the treatment paradigm across a variety of autoimmune diseases

EMERYVILLE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical

Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis

Wed, 03 Jun 2026 08:00:00 -0400

Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36

Single-dose of miv-cel delivered deep B-cell depletion with evidence of immune reset

Miv-cel continues to demonstrate a well-tolerated safety profile, consistent with observations from over 100 patients treated to date¹

Data reinforce miv-cel’s differentiated clinical profile and opportunity to change the treatment paradigm across a variety of autoimmune diseases

EMERYVILLE, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical

Form 8-K Kyverna Therapeutics, For: May 27

Tue, 02 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26592222.html

Form 8-K Kyverna Therapeutics, For: May 27

Tue, 02 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260602/26592222.html

Form 4 Kyverna Therapeutics, For: May 27 Filed by: SEIDENBERG BETH C